Weight loss in adulthood tied to reduced risk of colorectal adenoma
Feb 01, 2022
Weight loss from age 20 to age 55 to 74 years was linked to reduced risk, especially for those who were overweight or obese.
Prevalence of melatonin supplement use increased over time
Feb 01, 2022
1999-2000 to 2017-2018 saw an increase in reported prevalence of melatonin use across sex and age groups. A concern is that products sometimes contain more of the ingredient than specified on the label.
Remdesivir offers some benefit for hospitalized COVID-19 patients
Feb 01, 2022
No difference was seen for in-hospital mortality, but a need for initiation of mechanical ventilation was reduced with the addition of remdesivir to standard care.
SARS-CoV-2 antibody tests should not be used for diagnosis
Feb 01, 2022
A related review shows that recent infection protected against symptomatic reinfection with the wild-type or alpha variant of SARS-CoV-2.
‘Stealth’ version of omicron variant no cause for alarm, experts say
Jan 31, 2022
The new version of the variant does not appear to cause more severe disease, and vaccines are effective against it.
Physical activity monitors with feedback effective in adults
Jan 31, 2022
However, despite increased physical activity, no significant effect was seen on sedentary time.
Neutralization titers against omicron up with mRNA-1273 boost
Jan 28, 2022
After a mRNA-1273 (Moderna) boost, neutralization titers against the omicron variant were 20 times higher than than those at one month after second dose.
Flavonoid intake linked to mortality risk in Parkinson’s disease
Jan 28, 2022
Higher flavonoid intake after a diagnosis of Parkinson disease is linked to a reduced risk for all-cause mortality.
Likelihood of hospital admission up during foot ulcer episodes
Jan 28, 2022
All-cause inpatient admissions were 2.8 times more likely, and death was 1.5 times more likely, during foot ulcer episodes versus period after healing.
Thrombosis, thrombocytopenia syndrome up after Ad26.COV2.S
Jan 28, 2022
Rates of 3.83 per million vaccine doses for Ad26.COV2.S (Johnson & Johnson) have been reported, versus 0.00855 per million for mRNA-based vaccines such as Pfizer-BioNTech and Moderna.